CJC-1295 isn't found on pharmacy shelves in Hazen or virtually any local market — it's a research compound available through a dedicated online market. The core insight for Hazen researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the framework for evaluating that quality is the same regardless of where you are. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. The sections below cover what Hazen researchers need to know about finding, evaluating, and storing CJC-1295 for research purposes.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Hazen comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Before evaluating any specific vendor, establish a quality benchmark — so you can tell whether a COA is complete and credible. A COA for CJC-1295 should include: HPLC purity percentage with the full chromatographic trace, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all specific to the lot you receive. Community reputation in research forums is a useful additional signal to COA verification — vendors with consistently positive reports over 12+ months have built their reputation on real product performance. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order CJC-1295 — ships to Hazen
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human therapeutic use by the FDA or comparable health authorities — all information here is for educational purposes only. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution kept at 2-8°C refrigerated and used within 30 days; reconstitute only with bacteriostatic water. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at minute levels, and no cost saving makes omitting this acceptable. Protocol documentation — documenting product details, dates, and administration precisely — is a research best practice for CJC-1295 that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
